Dr. Nicholas T. Potter has been appointed to the Medical Advisory Board of Epigenomics AG, a molecular diagnostics company developing and commercializing tests for the screening and diagnosis of cancer.  Their lead product Epi proColon 2.0, a blood-based test for the early detection of colorectal cancer (CRC) which is currently marketed in Europe and in development in the US, was recently used  to support a pivotal clinical trial for CRC detection and will be submitted to the FDA for approval later this year.  He is currently the Chief Scientific Officer and Director of Molecular Diagnostics at Molecular Pathology Laboratory Network, Inc., in Maryville TN.